Bay Rivers Group raised its stake in Johnson & Johnson (NYSE:JNJ) by 26.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,491 shares of the company’s stock after acquiring an additional 729 shares during the period. Bay Rivers Group’s holdings in Johnson & Johnson were worth $564,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Newton One Investments LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $31,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $32,000. Robbins Farley LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $33,000. Lion Street Advisors LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $36,000. Finally, Alpha Paradigm Partners LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth about $47,000. Institutional investors own 67.14% of the company’s stock.
NYSE JNJ opened at $160.69 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 1.34 and a debt-to-equity ratio of 0.43. The firm has a market cap of $423.03 billion, a PE ratio of 24.02, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71. The company has a 50 day moving average price of $162.74 and a 200 day moving average price of $167.40. Johnson & Johnson has a 52 week low of $142.86 and a 52 week high of $179.92.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 7th. Shareholders of record on Tuesday, November 23rd will be paid a dividend of $1.06 per share. The ex-dividend date is Monday, November 22nd. This represents a $4.24 dividend on an annualized basis and a yield of 2.64%. Johnson & Johnson’s payout ratio is 63.38%.
JNJ has been the topic of several analyst reports. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price target on the stock. in a report on Tuesday, September 7th. SVB Leerink reissued a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Raymond James lowered their price objective on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, October 20th. Wells Fargo & Company reissued a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, October 7th. Finally, Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price objective for the company in a research report on Friday, October 22nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $187.78.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Read More: How dollar cost averaging works
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.